A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease that requires precise diagnosis for effective treatment. However, the diagnostic value of carbohydrate antigen 19 − 9 (CA19-9) is limited. Therefore, this study aims to identify novel tumor-associated autoantibodies (TAAbs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tiandong, Xia, Junfen, Yun, Huan, Sun, Guiying, Shen, Yajing, Wang, Peng, Shi, Jianxiang, Wang, Keyan, Yang, Hongwei, Ye, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655307/
https://www.ncbi.nlm.nih.gov/pubmed/37974212
http://dx.doi.org/10.1186/s12935-023-03107-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655307/
https://www.ncbi.nlm.nih.gov/pubmed/37974212
http://dx.doi.org/10.1186/s12935-023-03107-1

Ejemplares similares